8-K 1 mdrx-8k_20180521.htm FORM 8-K mdrx-8k_20180521.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2018

 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35547

36-4392754

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

222 Merchandise Mart Plaza, Suite 2024,

Chicago, Illinois 60654

(Address of Principal Executive Offices)  (Zip Code)

Registrant’s Telephone Number, Including Area Code: (312) 506-1200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


1


Item 5.07Submission of Matters to a Vote of Security Holders

At the 2018 Annual Meeting held on May 21, 2018, the stockholders of the Company voted on the following four proposals and cast their votes as described below:

 

1.

The individuals listed below were elected at the 2018 Annual Meeting to serve as directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified.

 

For

Against

Abstain

Broker Non-Vote

Mara G. Aspinall

153,940,820

2,738,656

271,634

10,582,499

Paul M. Black

155,670,029

1,007,858

273,223

10,582,499

P. Gregory Garrison

155,708,939

967,627

274,544

10,582,499

Jonathan J. Judge

154,432,139

2,239,886

279,085

10,582,499

Michael A. Klayko

154,429,638

2,246,285

275,187

10,582,499

Yancey L. Spruill

155,704,785

968,695

277,630

10,582,499

Dave B. Stevens

155,648,220

1,017,099

285,791

10,582,499

David D. Stevens

154,937,384

1,731,933

281,793

10,582,499

 

2.

A management proposal to approve an amendment and restatement of the Company’s Employee Stock Purchase Plan to, among other things, increase the number of shares available for grant thereunder, as described in the proxy materials, was approved.

For

Against

Abstain

Broker Non-Vote

156,039,339

677,193

234,578

10,582,499

 

3.

A management proposal to ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018, as described in the proxy materials, was approved.

For

Against

Abstain

Broker Non-Vote

166,505,937

746,374

281,298

0

 

4.

A non-binding, advisory resolution to approve named executive officer compensation, as described in the proxy materials, was approved.

For

Against

Abstain

Broker Non-Vote

147,592,288

9,079,243

279,579

10,582,499

  


2


 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date:  May 23, 2018 

 

 

By:

/s/ Brian P. Farley

 

 

Brian P. Farley

EVP, Chief Administrative Officer, General Counsel and Corporate Secretary

 

 

3